Literature DB >> 26223504

Gene expression profiling offers insights into the role of innate immune signaling in SSc.

Michael E Johnson1, Patricia A Pioli, Michael L Whitfield.   

Abstract

Systemic sclerosis (SSc) is characterized by inflammation, vascular dysfunction, and ultimately fibrosis. Progress in understanding disease pathogenesis and developing effective disease treatments has been hampered by an incomplete understanding of SSc heterogeneity. To clarify this, we have used genomic approaches to identify distinct patient subsets based on gene expression patterns in SSc skin and other end-target organs. Here, we review what is known about the gene expression-based subsets in SSc, currently defined as the inflammatory, fibroproliferative, limited, and normal-like subsets. The inflammatory subset of patients is characterized by infiltrating immune cells that include T cells, macrophages, and possibly dendritic cells, although little is known about the mediators these cells secrete and the pathways that govern cell activation. Prior studies have suggested a role for pathogens as a trigger of immune responses in SSc, and recent data have identified viral and mycobiome components as potential environmental triggers. We present a model based on analyses of gene expression data and a review of the literature, which suggests that the gene expression subsets observed in patients possibly represent distinct, interconnected molecular states of disease, to which an innate immune response is central that results in the generation of clinical disease.

Entities:  

Mesh:

Year:  2015        PMID: 26223504      PMCID: PMC4722533          DOI: 10.1007/s00281-015-0512-6

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  62 in total

1.  Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms.

Authors:  Ming O Li; Shomyseh Sanjabi; Richard A Flavell
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

2.  Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?

Authors:  Maki Murata; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Minoru Hasegawa; Kazuhiko Takehara; Kazuhiro Komura; Shinichi Sato
Journal:  J Dermatol Sci       Date:  2008-03-07       Impact factor: 4.563

3.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

4.  The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Authors:  Carol M Artlett; Sihem Sassi-Gaha; Judy L Rieger; Alina C Boesteanu; Carol A Feghali-Bostwick; Peter D Katsikis
Journal:  Arthritis Rheum       Date:  2011-11

Review 5.  Plasmacytoid dendritic cells: recent progress and open questions.

Authors:  Boris Reizis; Anna Bunin; Hiyaa S Ghosh; Kanako L Lewis; Vanja Sisirak
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

6.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

7.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors:  Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Journal:  Arthritis Res Ther       Date:  2010-07-05       Impact factor: 5.156

8.  Skin distribution and differential expression of transforming growth factor beta 1 and beta 2.

Authors:  V Falanga; C O Gerhardt; J R Dasch; K Takehara; G A Ksander
Journal:  J Dermatol Sci       Date:  1992-05       Impact factor: 4.563

9.  Immune complexes in progressive systemic sclerosis (scleroderma).

Authors:  J R Seibold; T A Medsger; A Winkelstein; R H Kelly; G P Rodnan
Journal:  Arthritis Rheum       Date:  1982-10

10.  Fibrosis in systemic sclerosis: common and unique pathobiology.

Authors:  Swati Bhattacharyya; Jun Wei; Warren G Tourtellotte; Monique Hinchcliff; Cara G Gottardi; John Varga
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
View more
  14 in total

Review 1.  Macrophages in Systemic Sclerosis: Novel Insights and Therapeutic Implications.

Authors:  Diana M Toledo; Patricia A Pioli
Journal:  Curr Rheumatol Rep       Date:  2019-05-23       Impact factor: 4.592

2.  Systemic Sclerosis and Pulmonary Disease.

Authors:  Khoa Ngo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.

Authors:  Swati Bhattacharyya; Kim S Midwood; Hang Yin; John Varga
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-10-01       Impact factor: 4.730

4.  Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.

Authors:  Monique Hinchcliff; Diana M Toledo; Jaclyn N Taroni; Tammara A Wood; Jennifer M Franks; Michael S Ball; Aileen Hoffmann; Sapna M Amin; Ainah U Tan; Kevin Tom; Yolanda Nesbeth; Jungwha Lee; Madeleine Ma; Kathleen Aren; Mary A Carns; Patricia A Pioli; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

5.  Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.

Authors:  Jennifer L Sargent; Zhenghui Li; Antonios O Aliprantis; Matthew Greenblatt; Raphael Lemaire; Ming-Hua Wu; Jun Wei; Jaclyn Taroni; Adam Harris; Kristen B Long; Chelsea Burgwin; Carol M Artlett; Elizabeth P Blankenhorn; Robert Lafyatis; John Varga; Stephen H Clark; Michael L Whitfield
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

Review 6.  Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.

Authors:  Viktor Martyanov; Michael L Whitfield
Journal:  Curr Opin Rheumatol       Date:  2016-01       Impact factor: 5.006

Review 7.  The Microbiome in Connective Tissue Diseases and Vasculitides: An Updated Narrative Review.

Authors:  Rossella Talotta; Fabiola Atzeni; Maria Chiara Ditto; Maria Chiara Gerardi; Piercarlo Sarzi-Puttini
Journal:  J Immunol Res       Date:  2017-08-01       Impact factor: 4.818

8.  Tenascin-C drives persistence of organ fibrosis.

Authors:  Swati Bhattacharyya; Wenxia Wang; Luisa Morales-Nebreda; Gang Feng; Minghua Wu; Xiaodong Zhou; Robert Lafyatis; Jungwha Lee; Monique Hinchcliff; Carol Feghali-Bostwick; Katja Lakota; G R Scott Budinger; Kirtee Raparia; Zenshiro Tamaki; John Varga
Journal:  Nat Commun       Date:  2016-06-03       Impact factor: 14.919

Review 9.  Pathophysiological Mechanisms in Sclerosing Skin Diseases.

Authors:  Beate Eckes; Fang Wang; Pia Moinzadeh; Nicolas Hunzelmann; Thomas Krieg
Journal:  Front Med (Lausanne)       Date:  2017-08-18

10.  Black, White, and Gray: Macrophages in Skin Repair and Disease.

Authors:  Melanie Rodrigues; Geoffrey Gurtner
Journal:  Curr Pathobiol Rep       Date:  2017-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.